Business Context and Reporting Period
InMed Pharmaceuticals Inc. (INM), an emerging growth company incorporated in British Columbia, Canada, filed this Form 8-K on December 17, 2025. The report details the results of the 2025 Annual General and Special Meeting of Shareholders held on the same date.
Key Financial Metrics
This filing is a current report regarding shareholder voting outcomes and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing notes that audited consolidated financial statements for the fiscal year ended June 30, 2025, were presented to shareholders but were not subject to a vote.
Material Changes and Voting Results
Shareholders voted on five proposals at the meeting. The results were as follows:
- Proposal 1 (Financial Statements): Presented for information only; no vote was taken.
- Proposal 2 (Election of Directors): All five nominees were elected. Support ranged from 81.94% to 82.11% of votes cast, with approximately 18% of votes withheld for each director.
- Proposal 3 (Appointment of Auditor): Shareholders approved the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm. The proposal received 78.84% of votes for, with 21.16% against.
- Proposal 4 (SEPA Share Issuance): Shareholders approved the potential issuance of 20% or more of outstanding common shares under the Standby Equity Purchase Agreement with YA II PN, Ltd. The proposal received 65.89% of votes for, with 34.11% against.
- Proposal 5 (Other Business): No other matters were voted upon.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure that the press release furnished as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act. The approval of the SEPA share issuance indicates the company's intent to maintain access to capital markets through the existing agreement with YA II PN, Ltd.
Investor Verification Checklist
- Verify the specific terms and remaining capacity of the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. following the shareholder approval.
- Review the audited consolidated financial statements for the fiscal year ended June 30, 2025, which were presented but not voted on, to assess the company's financial health.
- Monitor the company's cash position and burn rate, as the filing indicates no current revenue or profit data.
- Confirm the effective date and scope of the new auditor, CBIZ CPAs P.C., for the upcoming fiscal year.